Asthma is one of the most prevalent chronic inflammatory respiratory diseases across the globe, with a significant increase ...

Earlier this month, Apogee Therapeutics reported positive interim Phase 1b data for zumilokibart (APG777) in mild-to-moderate asthma, showing a favorable safety profile and durable suppression of Type ...

Good morning, and welcome to Apogee Therapeutics' Conference Call [Operator Instructions] Please be advised that this call is being recorded at the company's request. I will now turn the call over to ...

SAN FRANCISCO and BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for ...

FUTURE CHARGES ARE EXPECTED...RANGING FROM HUMAN TRAFFICKING TO CHILD ENDANGERMENT AND CUSTODIAL INTERFERENCE. GOOD MORNING AND HAPPY SUNDAY. WE HAVE PLENTY OF CLOUDS AROUND TO START THE DAY WITH A ...

A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...

An 8-year-old previously healthy female presents to the pediatrician’s office to establish care after recently moving to the United States from Peru 3 months ago. Past medical history is significant ...

Mild week ahead with morning fog possible. It'll feel more like January this weekend when a cold front arrives! Click and watch the forecast video for details. Starting around 7 a.m., resurfacing and ...

From Ramadan to Lent, fasting is as old as faith itself. But in recent years, millions of Americans have embraced intermittent fasting for better health. Some even claim it sharpens the mind. For ...

Please provide your email address to receive an email when new articles are posted on . Significantly fewer pediatric patients with low- vs. high-risk intermittent asthma had an ED visit and inhaled ...

As reliever monotherapy for mild asthma, the inhaled corticosteroid (ICS)-formoterol combination reduced asthma attacks in children compared with a short-acting β₂-agonist (SABA), the CARE trial ...